Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 16

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 16
---
 happen to MIRA’s options and restricted stock units in the Merger?

A: MIRA stock options and MIRA restricted stock units will remain outstanding and will not change in connection with the Merger.

Q: Who will be the directors of MIRA following the Merger?

A:At the Effective Time, the post-Merger company is expected to initially consist of four (4) of the five (5) current members of MIRA’s board of directors, comprised of Erez Aminov, Edward MacPherson, Matthew Whalen and Matthew del Guidice, with MIRA’s other current director, Denil Shekhat, being replaced with Kelly Stackpole, SKNY’s current CEO, each until their respective successors are duly elected or appointed and qualified or their earlier death, resignation or removal.

The aforementioned board of directors will have an audit committee, a compensation committee and a nominating and corporate governance committee, in accordance with the rules of The Nasdaq Stock Market LLC (“Nasdaq”).

Q: Who will be the executive officers of MIRA following the Merger?

A:Immediately following the Merger, the executive management team of the post-Merger company is expected to remain the same as MIRA pre-Merger:

| Name         |     | Position          
 with MIRA         |
| Erez         
 Aminov       |     | Chief             
 Executive Officer |
| Alan         
 Weichselbaum |     | Chief             
 Financial Officer |

| 4 |

Q: What risks should I consider in deciding whether to vote in favor of Proposal No. 1?

A: You should carefully review the section of the proxy statement titled “ Risk Factors,” which sets forth certain risks and uncertainties related to the Merger, risks and uncertainties to which the combined company’s business will be subject, and risks and uncertainties to which each of MIRA and SKNY, as an independent company, is subject.

Q: When do you expect the Merger to be consummated?

A:We anticipate that the Merger will be consummated during the third quarter of 2025, soon after the MIRA Annual Meeting to be held on , but we cannot predict the exact timing. For more information, please see the section titled “ The Merger

Agreement—Conditions to the Merger.”

Q: What are the material U.S. federal income tax consequences of the Merger to U.S. Holders of SKNY shares?

A:MIRA and SKNY intend the Merger to qualify as a